Autologous CAR-T cell immunotherapy for autoimmune diseases: a systematic review
Year: 2025
Type: article
Study design: Systematic Review
Abstract: Autologous CAR-T cell immunotherapy has emerged as a promising treatment for autoimmune disease, achieving high remission rates with manageable side effects. However, concerns remain regarding long-term safety, durability, and manufacturing scalability. Aim(s)/objectives: this systematic review assesses the therapeutic potential of autologous CAR-T cells. The feasibility of autologous CAR-T manufacturing and future directions will also be discussed. Methods: 27 studies (2019–2025) from 3 databases were reviewed to assess the clinical efficacy and safety of autologous CAR-T cells in autoimmune disease. Of 131 patients treated, 58% achieved complete remission, while an additional 35.8% demonstrated clinically significant improvement. Mild cytokine release syndrome (grades 1–2) was reported in 51.9% and 4.6% experienced immune effector cell-associated neurotoxicity syndrome. Other side effects, often linked to lymphodepleting chemotherapy, were manageable. Limitations of the review include a small sample size, a non-randomized design, and a short follow-up. Conclusions: CAR-T immunotherapy achieves effective remission of several autoimmune disorders with manageable toxicity. Larger, longer-term controlled trials are needed to confirm these findings and the durability of response. Emerging innovations like self-regulating CAR-T cells and manufacturing developments such as T-Charge™ and in vivo manufacturing may improve efficiency and scalability for widespread clinical use.
Source: Cell and Gene Therapy Insights
Authors: Tisha Singhal, John Maher
Institutions: King's College London, Guy's Hospital, Leucid Bio (United Kingdom)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4417245662
FWCI:
Cites:
Cited by:
Related to: